{4-[2-(4-(2-CHLOROQUINOXALIN-3-YL)PIPERAZIN-1-YL]ETHYL)PHENYL}-THIAZOL-2-AMINE

/static/temp/default.svg

Search structure


Molecule Category	Free-form
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	IXBGJKDOIYOBBV-UHFFFAOYSA-N
Smiles	Nc1nc(cs1)c2ccc(CCN3CCN(CC3)c4nc5ccccc5nc4Cl)cc2
InChI	InChI=1S/C23H23ClN6S/c24-21-22(27-19-4-2-1-3-18(19)26-21)30-13-11-29(12-14-30)10-9-16-5-7-17(8-6-16)20-15-31-23(25)28-20/h1-8,15H,9-14H2,(H2,25,28)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C23H23ClN6S
Molecular Weight	450.99
AlogP	4.93
Hydrogen Bond Acceptor	6.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	5.0
Polar Surface Area	99.41
Molecular species	NEUTRAL
Aromatic Rings	4.0
Heavy Atoms	31.0

Assay Description	Organism	Bioactivity	Reference
Selectivity ratio of inhibition of 5-HT2A receptor in Swiss albino Mus musculus (mouse) to inhibition of dopaminergic D2 receptor in Swiss albino Mus musculus (mouse) at 10 mg/kg, ip	Mus musculus	1.13
In vivo inhibition of dopaminergic D2 receptor in Swiss albino Mus musculus (mouse) at 10 mg/kg, ip relative to vehicle-treated control	Mus musculus	70.0 %
In vivo inhibition of 5-HT2A receptor in Swiss albino Mus musculus (mouse) at 10 mg/kg, ip relative to vehicle-treated control	Mus musculus	79.0 %
Displacement of [3H]spiperone from dopaminergic D2 receptor in Rattus norvegicus (rat) straitum membrane homogenates up to 1 uM after 60 min by liquid scintillation counting analysis	Rattus norvegicus	None
Displacement of [3H]ketanserin from 5-HT2A receptor in Rattus norvegicus (rat) cortex membrane homogenates up to 1 uM after 90 min by liquid scintillation counting analysis	Rattus norvegicus	None
Antagonist activity at nigrostriatal dopaminergic D2 receptor in Swiss albino Mus musculus (mouse) assessed as maximum average cataleptic time at 10 mg/kg, ip after 1 to 5 hr relative to vehicle-treated control	Mus musculus	18.24 s
Antagonist activity at central serotonergic 5-HT2A receptor in Swiss albino Mus musculus (mouse) assessed as inhibition of quipazine meleate-induced head twiches at 10 mg/kg, ip administered 1 hr prior to quipazine meleate challenge measured after 30 to 40 min relative to vehicle-treated control	Mus musculus	79.0 %
Antagonist activity at mesolimbic dopaminergic D2 receptor in Swiss albino Mus musculus (mouse) assessed as inhibition of apomorphine-induced cage climbing behavior at 10 mg/kg, ip administered 1 hr prior to apomorphine challenge measured after 30 min relative to vehicle-treated control	Mus musculus	70.0 %
Antagonist activity at mesolimbic dopaminergic D2 receptor in Swiss albino Mus musculus (mouse) assessed as inhibition of apomorphine-induced cage climbing behavior at 10 mg/kg, ip administered 1 hr prior to apomorphine challenge measured after 20 min relative to vehicle-treated control	Mus musculus	60.0 %
Antagonist activity at mesolimbic dopaminergic D2 receptor in Swiss albino Mus musculus (mouse) assessed as inhibition of apomorphine-induced cage climbing behavior at 10 mg/kg, ip administered 1 hr prior to apomorphine challenge measured after 10 min relative to vehicle-treated control	Mus musculus	65.0 %
Displacement of [3H]ketanserin from 5-HT2A receptor in Rattus norvegicus (rat) cortex membrane homogenates at 10 uM after 90 min by liquid scintillation counting analysis	Rattus norvegicus	4.0 %
Displacement of [3H]spiperone from D2 receptor in Rattus norvegicus (rat) straitum membrane homogenates at 100 uM after 60 min by liquid scintillation counting analysis	Rattus norvegicus	0.0 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2299236
PubChem	71577682

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).